Diabetes is a significant chronic disease that in limited studies has been linked with olfactory dysfunction. We investigated the cross-sectional association between diabetes and olfactory dysfunction in 3151 adults aged ≥40 years who participated in US National Health and Nutrition Examination Survey 2013-2014 with information on olfactory dysfunction and diabetes. Diabetes was defined from fasting serum glucose ≥126 mg/dL, oral glucose tolerance test ≥200 mg/dL, HbA1c levels ≥6.5%, physician-diagnosed diabetes, or current use of oral hypoglycemic agents and/or insulin. Self-reported olfactory dysfunction was defined as a positive answer to any of the following questions: 1) "Have you had problem with smell in the past 12 months?"; 2) "Have you had a change in the ability to smell since age 25?" , or 3) "Do you have phantom smells?" . Participants were considered to have severe hyposmia or anosmia if they had <5 correct answers in the 8-item pocket smell test. Analyses were adjusted for the main confounders, including olfactory dysfunction risk factors. Compared to non-diabetics, diabetics under insulin treatment showed a higher prevalence of phantom odors [OR(95% CI): 2.42 (1.16; 5.06)] and a non-significant higher prevalence of severe hyposmia/anosmia [OR(95% CI): 1.57 (0.89; 2.78)]. Amongst diabetics, there was a significant trend to severe hyposmia/anosmia for those on more aggressive treatments [OR (95% CI) including oral and insulin treatment compared to those who reported no use of drug treatment, respectively: 1.33 (0.60; 2.96) and 2.86 (1.28; 6.40); P trend 0.01]. No association was observed between diabetes duration and prevalence of olfactory dysfunction.
Introduction
Diabetes mellitus is a chronic disease that affects 14% of the US population (Menke et al. 2015) . Importantly, diabetes is associated with significant health-related complications including macrovascular complications of heart disease, stroke, peripheral vascular disease, and equally as important, microvascular complications including retinopathy, peripheral neuropathy, and renal disease (Manschot et al. 2006; Candrilli et al. 2007; Tiehuis et al. 2010) . These complications are a result of long standing poor glycemic control. The management of diabetes and its associated complications, a disease that is of significant burden to both patients and society, is a process that requires significant commitment from the patient including lifestyle modifications, weight loss, and compliance with medication (Inzucchi et al. 2015) .
Olfactory dysfunction indicates abnormalities in the conduction of olfactory stimuli externally to the olfactory epithelium or the sensory pathways arising from the olfactory epithelium. Manifestations of olfactory dysfunction may include phantosmia-the identification of smells in the absence of an external stimuli, parosmia-the identification of a smell that is incongruent with the external stimuli, hyposmia-a diminished ability to detect and identify smells, and anosmia-the inability to detect or identify smells. Amongst patients with diabetes, data suggests that olfactory dysfunction, alterations of the sensitivity of smell, may be a degenerative complication of diabetes (Le Floch et al. 1993; Weinstock et al. 1993; Palouzier-Paulignan et al. 2012; Varkonyi et al. 2014; Gouveri et al. 2014; Khil et al. 2015; Mehdizadeh Seraj et al. 2015; Duda-Sobczak et al. 2017) , secondary to the effects of this disease on the central nervous system (Biessels 2013; Bruce et al. 2013 ). There may also be reduced olfactory function in type 2 diabetics when compared with patients with type 1 diabetes (Palouzier-Paulignan et al. 2012; Gouveri et al. 2014) . If olfactory dysfunction in diabetics does result from central nervous system dysfunction, similar to the cognitive impairment and depression noted in diabetes (Biessels 2013; Bruce et al. 2013) , this suggests that olfactory testing may be helpful in the early recognition of diabetic complications (Brady et al. 2013; Gascon et al. 2013; Sanke et al. 2014) .
Recently, the US National Health and Nutrition Examination Survey (NHANES) included a smell component in the 2011-2014 chemosensory protocol using a standardized rapid smell assessment and smell questionnaire, with the data from the 2013-2014 cycle readily available. A previous study of the NHANES has shown increased risks for olfactory dysfunction dependent on age, ethnicity, socioeconomic status, education and alcohol consumption . Here, the aim of this study was to evaluate the association between diabetes and olfactory dysfunction in the US general population using NHANES.
Methods

Study design and population
Between 2013 and 2014, the NHANES examined a US nationally representative sample of 14 332 people by using a complex multistage sample design. Of those selected, 10 175 completed an interview. From these 10 175 participants, we excluded 6360 who were younger than 40 years, 305 without complete information on olfactory function, 147 with no information on diabetic status, and 212 with no information on potential confounders, leading to a sample size of 3151 participants. The NHANES protocol was reviewed and approved by the National Center for Health Statistics Institutional Review Board. Written informed consent was given by the participants for their clinical records to be used in a research study.
Study variables
The study variables and names are available in Supplementary  Table 1 .
Diabetes mellitus
Participants were considered diabetic if they had fasting serum glucose ≥126 mg/dL, oral glucose tolerance test ≥200 mg/dL, measured HbA1c levels ≥6.5%, self-reported diagnosis of diabetes, or current use of oral hypoglycemic agents or insulin. Study participants were categorized into 4 mutually exclusive groups: non-diabetics, diabetics who reported no use of oral hypoglycemic agents and/or insulin, diabetics treated with blood glucose lowering drugs, and diabetics treated with insulin regardless of their use of blood glucose lowering drugs. Participants with self-reported diagnosed diabetes were asked the age when first told they had diabetes.
Olfactory dysfunction
Self-reported olfactory dysfunction was defined as a positive answer to any of the following 3 questions: 1) "Have you had problem with smell in the past 12 months?"; 2) "Have you had a change in the ability to smell since age 25?" and 3) "Do you have phantom smells?" ( CDC 2013; Rawal et al. 2016) The 8-item pocket smell test was used to evaluate for the presence of anosmia or severe hyposmia (Sensonics International). The pocket smell test has been shown to be sensitive in identifying moderate to severe olfactory dysfunction and have good test-retest reliability (Rawal et al. 2015) . According to this test, participants were considered to have severe hyposmia or anosmia if they had less than 5 correct answers.
Sociodemographic variables, lifestyle, obesity, and reported comorbidity Sociodemographic variables included age, gender, ethnicity (nonHispanic White, non-Hispanic Black, Mexican American, Other), and education level (< high school, high school or equivalent, > high school). Participants were classified as never smokers if they had not smoked ≥100 cigarettes during a lifetime, and as ever smokers if they had done so but were not current smokers at the time of the interview. Participants were asked about their previous history of cardiovascular disease (congestive heart failure, coronary heart disease, heart attack, stroke), hypertension, head, or face injury, xerostomia (persistent dry mouth in past 12 months) and sinonasal symptoms (persistent cold/flu/nasal congestion in past 12 months, presence of 2 or more sinus infections). Hypertension was defined as a systolic blood pressure ≥140 mmHg, a diastolic blood pressure ≥90 mmHg, or the current use of antihypertensive drugs. The body mass index (BMI) was calculated as the weight in kg divided by the square height in metres.
Statistics
All statistical analyses were performed in STATA version 11.2 statistical software (Stata Corp), using the survey (svy) command to account for the complex sampling design and weights in NHANES. The prevalence of olfactory dysfunction was calculated overall and by sex, age, ethnicity, education, tobacco consumption, BMI, presence of sinonasal symptoms, xerostomia, previous history of head/ face injury, hypertension, or cardiovascular disease.
To evaluate the association between diabetes and olfactory dysfunction, odds ratios (OR) and 95% confidence intervals (95% CI) were estimated using logistic regression. Three models were built. In the basic model, we considered age, gender, and race. We then fitted 2 models by progressively adding: 1) potential confounders of the association between diabetes and olfactory dysfunction (educational level, smoking status, presence of sinonasal symptoms, xerostomia, previous history of head, or face injury); and 2) potential mediators of diabetes microvascular and macrovascular complications (hypertension, obesity, and cardiovascular disease). In sensitivity analyses, we also adjusted for additional sociodemographic factors (marital status, poverty to income ratio) and cardio-metabolic biomarkers (high density lipoprotein (HDL) and low density lipoprotein (LDL) cholesterol), with similar findings. The association between diabetes duration and olfactory dysfunction was assessed using logistic regression models with the same confounders as mentioned above. Statistical significance was set at 2-sided P < 0.05.
Results
The weighted prevalence of self-reported and measured olfactory dysfunction in the US population were 21.5% and 13.1%, respectively. Individuals with self-reported olfactory dysfunction were more likely to be smokers, obese, have a history of head/face injury, xerostomia, sinonasal symptoms, or cardiovascular disease. Individuals with measured olfactory dysfunction were more likely to be male, older, non-white, <high school education, have xerostomia, hypertension, and cardiovascular disease (Supplementary Table 2 ).
In fully adjusted models for sociodemographic, lifestyle, and olfactory dysfunction risk factors, diabetics who used insulin showed a higher prevalence of phantom odors than non-diabetics [OR: 2.98 (95% CI: 1.41; 6.32); Model 2, Amongst diabetics (Table 2) , there was a significant trend to severe hyposmia/anosmia for those on more aggressive treatments [ORs (95% CI) for participants on oral or insulin treatment compared to those who reported no use of drug treatment were, respectively, 1.30 (0.59; 2.90) and 2.87 (1.26; 6.52); P trend 0.01]. The increased prevalence of hyposmia/anosmia among those with diabetes was not explained by the increased prevalence of obesity, hypertension, and cardiovascular disease observed among diabetics (the change in the OR after adjustment for these factors was only of 0.5% [(1.30-1.33 Model 1: Logistic regression model adjusted for age (continuous), gender, and race. Model 2: As model 1 and additionally adjusted for educational level, smoking status, sinonasal symptoms, xerostomia, and previous history of head or face injury. Model 3: As model 2 and additionally adjusted for potential mediators: BMI, hypertension and cardiovascular disease. CI, confidence interval.
a Self-reported olfactory dysfunction was defined as a positive answer to any of the following questions: 1) Have you had problem with smell in the past 12 months?; 2) Have you had a change in the ability to smell since age 25? or; 3) Do you have phantom smells?
b Measured olfactory dysfunction (presence of severe hyposmia or anosmia) was defined as having less than 5 correct answers in the 8 item pocket smell test.
association observed between diabetes duration and prevalence of hyposmia/anosmia as shown in Supplementary Table 3) . In sensitivity analyses, additional adjustments for race, poverty income ratio, total serum cholesterol or serum high-density lipoprotein cholesterol, did not substantially change our results (data not shown in tables).
Discussion
To our knowledge, this is the first nationally representative study to evaluate the association between diabetes and olfactory function in the United States. Results suggest that, compared to non-diabetics, diabetics on insulin medication have a higher prevalence of phantom odors, severe hyposmia, and anosmia. Additionally, they show that, amongst diabetics, there is a significant trend to severe hyposmia and anosmia for those on more aggressive treatments. However, they do not suggest an association between duration of diabetes and development of olfactory dysfunction.
Several mechanisms may explain the observed associations. First, hyperglycaemia has been shown to result in increased cortical thinning of the orbitofrontal cortex, and type 2 diabetes has shown to be associated with significant atrophy of cortical and subcortical regions of the brain, accelerated cognitive decline (McCrimmon et al. 2012; Musen et al. 2012) , and neural connectivity abnormalities (Cui et al. 2015) . Phantosmia is thought to be related to reduced grey-matter volume at the insular cortex, cingulate cortex, hippocampus, and orbitofrontal cortex (Bitter et al. 2011) , and so diabetes could increase its risk by also affecting the orbitofrontal cortex (Ajilore et al. 2010) . Second, macrovascular disease may explain the increased prevalence of severe olfactory dysfunction. In this sense, controlling for cardiovascular disease and hypertension attenuated the effect of diabetes on phantosmia. However, macrovascular disease did not explain the increased risk of severe olfactory dysfunction noted in diabetics. Third, insulin resistance in the olfactory bulb and orbitofrontal cortex potentially could also play a role in olfactory dysfunction (De Felice et al. 2014) . In this sense, there is evidence that insulin regulates the olfactory mucosa physiology (Lacroix et al. 2008) and that intranasal insulin may improve olfactory sensitivity and discrimination (Schopf et al. 2015) . This third mechanism is supported by the fact that the odds of severe olfactory dysfunction was more likely in diabetics on insulin as opposed to those treated conservatively or oral medication. Model 1: Logistic regression model adjusted for age (continuous), gender, race, and duration of diabetes. Model 2: As model 1 and additionally adjusted for educational level, smoking status, sinonasal symptoms, xerostomia, and previous history of head or face injury. Model 3: As model 2 and additionally adjusted for potential mediators: BMI, hypertension and cardiovascular disease. CI, confidence interval.
a Self-reported olfactory dysfunction was defined as a positive answer to any of the following questions: 1) Have you had problem with smell in the past 12 months?; 2) Have you had a change in the ability to smell since age 25? or; 3) Do you have phantom smells? b Measured olfactory dysfunction (presence of hyposmia or anosmia) was defined as having less than 5 correct answers in the 8-item pocket smell test.
In regards to the association between type 2 diabetes mellitus with cognitive impairment and dementia , olfactory dysfunction has been demonstrated to predate clinical manifestations of cognitive impairment or Alzheimer's disease and may be an early marker of the development of cognitive impairment (Serby et al. 1991; Mesholam et al. 1998) . Furthermore, olfactory dysfunction and cognitive impairment in elderly patients with type 2 diabetes mellitus has been shown to be associated (Sanke et al. 2014 ). With our current findings of olfactory dysfunction amongst diabetics in a large population based database, further investigation about cognitive impairment in this group is warranted when cognitive function data becomes available on the NHANES database. These findings also suggest that evaluating olfactory dysfunction in diabetic patients may have a potential in predicting the development of cognitive impairment amongst diabetics.
Limitations of the current study may include residual confounding by unmeasured factors unaccounted for in our analyses that may underlie the observed associations. In this sense, for example, we could not adjust for important risk factors of diabetes such as physical inactivity or total calorie intake due to a large number of missing data. The cross-sectional study design precludes our ability to determine temporality or causation. The pocket smell test utilized in the NHANES may not be truly reflective of the degree of olfactory dysfunction as compared to a more extensive test such as the Sniffin' Stick or University of Pennsylvania Smell Identification Test smell test. The NHANES interview data are based on self-reports and may be subject to misunderstanding of the questions or recall bias. We were also not able to distinguish between adults with type 1 and type 2 diabetes. However, previous work has demonstrated that type 2 diabetes is the more predominant and likely representative of US adults (Cowie et al. 2009; Roy and Lloyd 2012) . The NHANES dataset from the 2013-2014 cycle also did not allow for the identification of patients with microvascular complications from diabetes. The NHANES results are limited to the US civilian household non-institutionalized adult population and may not completely represent the US population. Finally, NHANES data may not be completely reflective of actual clinical practice, and the risk of diabetes in clinical populations may differ.
Despite these methodological limitations, the results of our study provide the only population based estimates of self-reported and measured olfactory dysfunction amongst adults with diabetes in the US which will be valuable for future developments in the diagnosis and monitoring of diabetic complications. The objective assessment of olfactory dysfunction as opposed to self-reported information alone and the size of the diabetic population examined support the associations that have been identified in this study.
In conclusion, the results suggest that diabetes may be associated with olfactory dysfunction, in particular with the appearance of phantom odors, severe hyposmia, or anosmia. This information may be useful both for the diagnosis and monitoring of disease control amongst diabetics and warrants further investigations of the mechanisms involved.
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Supplementary data are available at Chemical Senses online.
